Myomo (NYSEAMERICAN:MYO) Announces Earnings Results, Beats Estimates By $0.01 EPS

Myomo (NYSEAMERICAN:MYO) posted its quarterly earnings results on Monday. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01, Zacks reports. The business had revenue of $12.33 million during the quarter, compared to the consensus estimate of $11.51 million. Myomo had a negative return on equity of 152.04% and a negative net margin of 33.14%.

Here are the key takeaways from Myomo’s conference call:

• Revenue reached a record $12.3 million, up 22% year over year, while gross margin increased to 71.3% from 63.8% and adjusted EBITDA reached approximately break-even.
• Recurring patient sources rose to 54% of revenue from 33% a year ago, and MyoConnect had referrals from more than 500 facilities. The company also reported a record 258 orders and payer agreements or pending agreements covering an additional 35 million lives.
• Myomo narrowed its 2026 revenue outlook to $46 million–$47 million, from the prior $45 million–$47 million range, and expects second-half cash burn below $2 million. Management expects a modest sequential gross-margin increase in Q4, though operating expenses are expected to rise modestly.
• Pipeline additions fell to 600, with management citing summer-season effects, temporary MyoConnect staffing constraints, and inefficient direct-to-patient lead generation. October direct-billing pipeline additions improved about 30% from the Q3 monthly average, but Q4 pipeline activity is typically seasonally lower.
• Net loss was $4.2 million versus $3.7 million a year earlier, despite a narrower operating loss; results included an approximately $1.8 million non-cash derivative-liability valuation charge and interest expense tied to the term loan.

Myomo Price Performance

Shares of NYSEAMERICAN:MYO opened at $1.27 on Wednesday. The firm has a 50 day moving average of $1.38 and a 200-day moving average of $1.09. Myomo has a 12 month low of $0.60 and a 12 month high of $1.89. The company has a current ratio of 2.31, a quick ratio of 2.01 and a debt-to-equity ratio of 1.98. The stock has a market capitalization of $50.30 million, a PE ratio of -3.63 and a beta of 1.74.

Insider Activity

In related news, insider Harry Kovelman sold 17,250 shares of the stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $1.73, for a total transaction of $29,842.50. Following the sale, the insider owned 105,983 shares in the company, valued at approximately $183,350.59. This trade represents a 14.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last quarter, insiders have sold 47,738 shares of company stock worth $70,662. Company insiders own 12.14% of the company’s stock.

Myomo Company Profile

Myomo, Inc. is a medical device company that develops and markets wearable robotic braces designed to help individuals with impaired upper-limb function regain movement and perform activities of daily living. Its principal product is the MyoPro, a lightweight, electrically powered orthosis that detects a user’s residual muscle signals and assists movement of the arm and hand. The MyoPro is intended for people affected by neuromuscular disorders and injuries, including stroke, brachial plexus injury, multiple sclerosis, traumatic brain injury and spinal cord injury.